Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma

Although BRAF and MEK inhibitors have proven clinical benefits in melanoma, most patients develop resistance. We report a de novo MEK2-Q60P mutation and BRAF gain in a melanoma from a patient who progressed on the MEK inhibitor trametinib and did not respond to the BRAF inhibitor dabrafenib. We also...

Full description

Bibliographic Details
Main Authors: Jessie Villanueva, Jeffrey R. Infante, Clemens Krepler, Patricia Reyes-Uribe, Minu Samanta, Hsin-Yi Chen, Bin Li, Rolf K. Swoboda, Melissa Wilson, Adina Vultur, Mizuho Fukunaba-Kalabis, Bradley Wubbenhorst, Thomas Y. Chen, Qin Liu, Katrin Sproesser, Douglas J. DeMarini, Tona M. Gilmer, Anne-Marie Martin, Ronen Marmorstein, David C. Schultz, David W. Speicher, Giorgos C. Karakousis, Wei Xu, Ravi K. Amaravadi, Xiaowei Xu, Lynn M. Schuchter, Meenhard Herlyn, Katherine L. Nathanson
Format: Article
Language:English
Published: Elsevier 2013-09-01
Series:Cell Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124713004646

Internet

http://www.sciencedirect.com/science/article/pii/S2211124713004646

Similar Items